The purpose of the project is to characterize the molecular landscape of a set of 28 malignant melanomas using next-generation sequencing, identify the prevalence and nature of class 3-5 variants (e.g., <i>NRAS</i>, <i>BRAF</i>, <i>KIT</i>, <i>TP53</i>), assess the genetic complexity and molecular patterns, and use these insights to inform personalized therapies and optimize patient stratification for potential combination strategies (targeted therapy followed by immunotherapy). Here, BRAF is linked to cancer.